Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 811 to 825 of 2581 results for methods

  1. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development Reference number: GID-QS10146 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Infant, children and young people's experience of health care

    Awaiting development Reference number: GID-QS10102 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Primary hyperparathyroidism

    Awaiting development Reference number: GID-QS10089 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Hemosep for cell salvage (MIB103)

    NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .

    Medtech innovation briefing
    Published
    3 May 2017

  10. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    quality of life. In order to make informed choices about the most appropriate method of bladder management, patients and/or their family...

    Research recommendation
    Published
    9 June 2015

  11. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  12. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

    Technology appraisal guidance
    In development

  13. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  14. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  15. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development